us market wants this technology, page-2

Gee I may be the genius but Cafe - you are right on the money. Did you see the deal lthat was announcemed last night?

Read below;

15 May 2006
AstraZeneca announces major long-term strategic investment in biological therapeutics
with a recommended £702 million cash offer for Cambridge Antibody Technology Group plc
at 1,320p per share and 1,320p per ADS
Summary
The boards of AstraZeneca and CAT announce that they have agreed terms of a recommended
cash offer to be made by AstraZeneca to acquire the entire issued and to be issued share capital
of CAT not otherwise held by AstraZeneca. The Offer for each CAT Share will be at 1,320 pence
in cash and the Offer for each CAT ADS will be at 1,320 pence in cash, equivalent to US$24.96
per ADS (based on the exchange rate as at 12 May 2006). The Offer values CAT’s existing issued
share capital, excluding AstraZeneca’s existing shareholding in CAT, at approximately £567 million
and the entire issued share capital of CAT at approximately £702 million.
Building on the success of an existing collaboration, and recognising the increasing importance of
biotechnology in medical research, CAT will become central to AstraZeneca’s plans to establish a
major international presence in the research and development of biological therapeutics.
AstraZeneca’s science base already possesses discovery and development capabilities for new
biological medicines which will be combined with those of CAT and expanded through further
investment. This enhanced research capability, combined with AstraZeneca’s global development,
marketing and sales resources, will establish an international platform capable of accelerating the
delivery of new medicines in AstraZeneca’s prioritised disease areas, embracing both monoclonal
antibodies and novel biological entities.